Autoimmune hepatitis - Causes, Treatment & When to See a Doctor

```html

What is Autoimmune Hepatitis?

Autoimmune hepatitis (AIH) is a chronic inflammatory disease of the liver in which the immune system mistakenly attacks liver cells (hepatocytes). This immune‑mediated attack causes liver inflammation, which can lead to fibrosis, cirrhosis, and eventually liver failure if left untreated. AIH can affect people of any age, gender, or ethnic background, but it occurs most often in women (about 70 % of cases) and typically presents in the second to fourth decades of life.

The exact cause is unknown, but genetic susceptibility combined with environmental triggers appears to set off an abnormal immune response. Unlike viral hepatitis, AIH is not caused by an infection and does not spread from person to person.

Common Causes

While AIH itself is not “caused” by another disease, several conditions and factors can increase the risk of developing it or can mimic its presentation. The following list includes eight to ten recognized associations:

• Genetic predisposition: Certain HLA (human leukocyte antigen) types, especially HLA‑DR3 and HLA‑DR4, are linked with higher AIH risk.
• Other autoimmune diseases: Thyroiditis, type‑1 diabetes, rheumatoid arthritis, Sjögren’s syndrome, and celiac disease frequently coexist with AIH.
• Drug‑induced liver injury: Medications such as minocycline, nitrofurantoin, and certain herbal supplements can trigger an autoimmune‑like hepatitis.
• Viral infections: Hepatitis C, Epstein‑Barr virus, and cytomegalovirus have been reported as possible triggers, likely by molecular mimicry.
• Environmental toxins: Exposure to industrial chemicals (e.g., carbon tetrachloride) may initiate immune dysregulation.
• Pregnancy: Hormonal changes can unmask or exacerbate AIH in susceptible women.
• Vaccinations (rare): In isolated reports, certain vaccines have preceded AIH onset; causality remains unproven.
• Family history of autoimmunity: A first‑degree relative with any autoimmune disease raises individual risk.
• Liver‑specific antibodies: Presence of ANA, SMA, or LKM‑1 antibodies does not cause AIH, but they are markers indicating an immune‑mediated process.
• Age‑related immune changes: Immune senescence in older adults can modify disease presentation, sometimes leading to a milder, “autoimmune‑type” hepatitis.

Associated Symptoms

Symptoms of AIH develop gradually and are often nonspecific, which can delay diagnosis. Commonly reported manifestations include:

• Fatigue and generalized weakness
• Jaundice (yellowing of the skin and eyes)
• Dark urine and pale stools
• Upper‑right abdominal discomfort or fullness
• Loss of appetite and unintentional weight loss
• Joint pain or arthralgias (often associated with other autoimmune disorders)
• Itchy skin (pruritus) due to bile salt accumulation
• Fever or flu‑like feeling during active flares

Because early disease may be silent, many patients are first identified through abnormal liver‑function tests (elevated ALT, AST, and bilirubin) discovered on routine blood work.

When to See a Doctor

Prompt medical evaluation is crucial if you notice any of the following:

• Persistent yellowing of the eyes or skin
• Dark urine or light‑colored stool lasting more than a week
• Unexplained, continuous fatigue that interferes with daily activities
• Sudden, severe abdominal pain in the upper right quadrant
• Swelling in the abdomen or legs (signs of fluid retention)
• Unexplained weight loss or loss of appetite lasting >2 weeks
• Joint swelling or rash accompanied by liver‑related symptoms

If you have a known autoimmune disease and develop any liver‑related signs, seek care even sooner, as the risk of AIH is higher in this population.

Diagnosis

AIH diagnosis requires a combination of laboratory, imaging, and histologic findings. The most widely used criteria are the International Autoimmune Hepatitis Group (IAIHG) scoring system.

1. Blood Tests

• Liver enzymes: ALT and AST are typically >5–10 × the upper limit of normal.
• Bilirubin: Elevated in moderate to severe disease.
• Autoantibodies:
  • ANA (antinuclear antibody) – positive in 70–80 % of cases
  • SMA (smooth muscle antibody) – positive in 60–70 %
  • LKM‑1 (liver‑kidney microsomal) – seen mainly in type 2 AIH, more common in children
  • Soluble liver antigen (SLA) – highly specific, especially in seronegative patients
• Immunoglobulin G (IgG): Elevated IgG levels support an autoimmune process.
• Exclusion tests: Viral hepatitis panels, metabolic liver disease screens, and iron studies are performed to rule out other causes.

2. Imaging

Ultrasound, CT, or MRI are used to assess liver size, rule out biliary obstruction, and detect focal lesions. Imaging does not diagnose AIH but helps exclude alternate diagnoses.

3. Liver Biopsy

The gold standard. Typical histologic features include:

• Interface hepatitis (inflammation at the junction of portal tracts and hepatic lobules)
• Lymphoplasmacytic infiltrates
• Rosetting of hepatocytes
• Variable fibrosis, ranging from none to early cirrhosis

Biopsy also helps grade disease activity and stage fibrosis, guiding treatment intensity.

Treatment Options

AIH is a treatable condition. The primary goal is to suppress the immune attack, achieve biochemical remission, and prevent progression to cirrhosis.

Medical Therapies

• Corticosteroids (Prednisone): First‑line induction therapy. Starts at 30–60 mg daily, then tapered based on response.
• Azathioprine: A steroid‑sparing immunosuppressant added after 2–4 weeks. Typical dose 1–2 mg/kg/day.
• Mycophenolate mofetil (MMF): Considered when patients are intolerant to azathioprine or have relapsing disease.
• Budesonide: A locally acting steroid with fewer systemic side effects; suitable for non‑cirrhotic patients.
• Calcineurin inhibitors (Tacrolimus, Cyclosporine): Reserve for refractory disease.
• Biologic agents (Rituximab, Infliximab): Emerging options for severe, treatment‑resistant cases; used under specialist supervision.

Home & Lifestyle Measures

• Medication adherence: Never miss doses; abrupt withdrawal can cause flare‑ups.
• Balanced diet: Emphasize fruits, vegetables, lean protein, and whole grains; limit saturated fats and simple sugars.
• Avoid alcohol: Even moderate intake can worsen liver inflammation.
• Vaccinations: Stay up‑to‑date on hepatitis A & B, influenza, and pneumococcal vaccines (consult your hepatologist first).
• Regular exercise: Moderate activity (e.g., brisk walking 150 min/week) supports overall health without over‑taxing the liver.
• Weight management: Obesity adds stress to the liver; aim for a healthy BMI.
• Herb & supplement caution: Many over‑the‑counter products are hepatotoxic; discuss any supplements with your doctor.

Prevention Tips

Because AIH is an autoimmune condition, it cannot be completely prevented, but risk can be reduced and flares minimized:

• Maintain regular follow‑up with a hepatologist or gastroenterologist.
• Control co‑existing autoimmune diseases aggressively (e.g., thyroiditis, celiac disease).
• Limit exposure to known hepatotoxins such as excessive alcohol, illicit drugs, and unsafe herbal products.
• Adopt a liver‑friendly diet rich in antioxidants (berries, leafy greens) and omega‑3 fatty acids (fatty fish).
• Practice good hygiene to lower the chance of viral hepatitis infections.
• Manage stress—stress hormones can influence immune regulation; consider mindfulness, yoga, or counseling.
• If you are prescribed medications known to trigger autoimmune‑like hepatitis (e.g., nitrofurantoin), discuss alternatives with your prescribing physician.

Emergency Warning Signs

Key Take‑aways

Autoimmune hepatitis is a chronic, immune‑mediated liver disease that can be effectively controlled with medication and lifestyle measures. Early detection—often through routine blood work—prevents irreversible liver damage. If you notice liver‑related symptoms, especially in the setting of another autoimmune disorder, contact a healthcare professional promptly. With adherence to therapy and regular monitoring, most patients achieve long‑term remission and maintain a good quality of life.

References:

• Mayo Clinic. Autoimmune Hepatitis. https://www.mayoclinic.org
• Cleveland Clinic. Autoimmune Hepatitis Overview. https://my.clevelandclinic.org
• American Association for the Study of Liver Diseases (AASLD). Guidelines for the Management of Autoimmune Hepatitis. https://aasld.org
• National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Autoimmune Hepatitis. https://www.niddk.nih.gov
• World Health Organization. Hepatitis Fact Sheets. https://www.who.int

```